Similar transplant outcomes between haploidentical and unrelated donors after reduced-intensity conditioning with busulfan, fludarabine, and anti-thymocyte globulin in patients with acute leukemia or myelodysplastic syndrome.
Anti-thymocyte globulin
HLA-matched unrelated donor
Haploidentical stem cell transplantation
Reduced-intensity conditioning
Journal
Blood research
ISSN: 2287-979X
Titre abrégé: Blood Res
Pays: Korea (South)
ID NLM: 101605247
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
27
07
2019
revised:
12
12
2019
accepted:
03
02
2020
entrez:
10
4
2020
pubmed:
10
4
2020
medline:
10
4
2020
Statut:
ppublish
Résumé
Although T-cell-replete hematopoietic cell transplantation (HCT) from haploidentical donors (HIDs) using anti-thymocyte globulin (ATG) has shown promising outcomes, previous studies often adopted heterogenous graft sources and conditioning. We retrospectively compared HCT outcomes from 62 HIDs, 36 partially-matched unrelated donors (PUDs), and 55 matched unrelated donors (MUDs) in patients with acute leukemia or myelodysplastic syndrome using the same graft source of peripheral blood and a reduced intensity conditioning of busulfan, fludarabine, and ATG. The estimates of 3-yr disease-free survival (DFS) and overall survival (OS) rates were not significantly different among the MUD, HID, and PUD groups, at 46%, "41%, and 36%" for the DFS rate ( T-cell replete HCT from HIDs using an ATG-containing reduced intensity conditioning regimen may be a reasonable option in the absence of matched related donors in patients with acute leukemia or myelodysplastic syndrome.
Sections du résumé
BACKGROUND
BACKGROUND
Although T-cell-replete hematopoietic cell transplantation (HCT) from haploidentical donors (HIDs) using anti-thymocyte globulin (ATG) has shown promising outcomes, previous studies often adopted heterogenous graft sources and conditioning.
METHODS
METHODS
We retrospectively compared HCT outcomes from 62 HIDs, 36 partially-matched unrelated donors (PUDs), and 55 matched unrelated donors (MUDs) in patients with acute leukemia or myelodysplastic syndrome using the same graft source of peripheral blood and a reduced intensity conditioning of busulfan, fludarabine, and ATG.
RESULTS
RESULTS
The estimates of 3-yr disease-free survival (DFS) and overall survival (OS) rates were not significantly different among the MUD, HID, and PUD groups, at 46%, "41%, and 36%" for the DFS rate (
CONCLUSION
CONCLUSIONS
T-cell replete HCT from HIDs using an ATG-containing reduced intensity conditioning regimen may be a reasonable option in the absence of matched related donors in patients with acute leukemia or myelodysplastic syndrome.
Identifiants
pubmed: 32269972
doi: 10.5045/br.2020.55.1.27
pmc: PMC7106115
doi:
Types de publication
Journal Article
Langues
eng
Pagination
27-34Informations de copyright
© 2020 Korean Society of Hematology.
Déclaration de conflit d'intérêts
Authors' Disclosures of Potential Conflicts of Interest: No potential conflicts of interest relevant to this article were reported.
Références
Biol Blood Marrow Transplant. 2002;8(5):257-60
pubmed: 12064362
Bone Marrow Transplant. 2017 Jun;52(6):811-817
pubmed: 28287639
N Engl J Med. 2016 May 12;374(19):1894-5
pubmed: 27168441
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
Blood. 2011 Jun 9;117(23):6375-82
pubmed: 21467544
Blood. 2015 Feb 19;125(8):1333-8
pubmed: 25593335
Transplantation. 1974 Oct;18(4):295-304
pubmed: 4153799
Blood. 2013 Jan 31;121(5):849-57
pubmed: 23165479
Blood. 2014 Jun 5;123(23):3664-71
pubmed: 24744269
N Engl J Med. 1998 Oct 22;339(17):1177-85
pubmed: 9780337
Biol Blood Marrow Transplant. 2016 Aug;22(8):1403-1409
pubmed: 27095692
N Engl J Med. 2006 Apr 27;354(17):1813-26
pubmed: 16641398
Blood. 2014 Oct 23;124(17):2735-43
pubmed: 25214441
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Blood Rev. 2015 Mar;29(2):63-70
pubmed: 25307958
Blood. 2011 Sep 1;118(9):2609-17
pubmed: 21715313
Blood Adv. 2017 Feb 28;1(7):477-485
pubmed: 29296964
Blood. 2015 May 7;125(19):3024-31
pubmed: 25814532
Haematologica. 2016 Oct;101(10):1260-1266
pubmed: 27354023
Cancer. 2017 Aug 1;123(15):2881-2892
pubmed: 28301690
Biol Blood Marrow Transplant. 2017 Sep;23(9):1555-1566
pubmed: 28552421
N Engl J Med. 1985 Sep 26;313(13):765-71
pubmed: 3897863
Biol Blood Marrow Transplant. 2014 Oct;20(10):1573-9
pubmed: 24910379
Blood. 2015 Jun 18;125(25):3956-62
pubmed: 25940714
Lancet. 1983 Mar 19;1(8325):612-5
pubmed: 6131300
J Hematol Oncol. 2017 Jan 19;10(1):24
pubmed: 28103944